Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of Anti-COVID-19 Immune Globulin (Human) 20% (C19-IG 20%) Versus Placebo in Asymptomatic Ambulatory Outpatients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Conditions
Interventions
C19-IG 20%
0.9% Sodium chloride
Locations
12
Spain
CAP Gornal
L'Hospitalet de Llobregat, Barcelona, Spain
CAP Navàs
Navàs, Barcelona, Spain
CAP Sant Fèlix
Sabadell, Barcelona, Spain
Centro de Salud Nuestra Señora del Pilar
Alcalá de Henares, Madrid, Spain
Centro de Salud Presentación Sabio
Móstoles, Madrid, Spain
CAP Manso
Barcelona, Spain
Start Date
April 28, 2021
Primary Completion Date
November 10, 2021
Completion Date
December 27, 2021
Last Updated
December 5, 2022
NCT06631287
NCT04565665
NCT04978571
NCT06082518
NCT07221162
NCT06679140
Lead Sponsor
Grifols Therapeutics LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions